StockData
Autolus Therapeutics plc logo

Autolus Therapeutics plc (AUTL) stock

AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3020% below fair value
$1.09−0.05 (-4.39%)

Close on Nov 17, 2026Market cap $290.12MP/E –Yield –

Autolus Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Autolus Therapeutics's total debt was $380.00K at Sep 30, 2018. For fiscal 2018 it was $380.00K, down 50.2% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2018Sep 30, 2018$380.00K-50.2%
FY2017Sep 30, 2017$763.00K–

Quarterly total debt

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2018CQ3 2018Sep 30, 2018$380.00K–
Q4 FY2017CQ3 2017Sep 30, 2017$763.00K–

More Autolus Therapeutics figures

See a number that looks wrong?